Endometrial Cancer | Norton Healthcare

Indication: Endometrial Cancer

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery with Curative Intent (MK3475 B21/ENGOT-en11/GOG-3053)

Sub-indication: Gynecologic Cancer

Study Type: Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Merck Sharp & Dohme CORP

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.